Endemic mycoses: epidemiology and diagnostic strategies

Tirado‐Sánchez, Andrés; González, Gloria M.; Bonifáz, Alexandro

doi:10.1080/14787210.2020.1792774

Cited by 15 publications

(22 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ere are alterations in laboratory tests; being nonspecific findings, tests usually show anemia, leukopenia, thrombocytopenia, and elevated liver enzymes. In our series, neutropenia predominated in 41%, two patients with severe neutropenia <500 cells/mm 3 , and 5 patients with abnormal liver function tests [13].…”

Section: Discussionmentioning

confidence: 44%

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Solís

Santibáñez

Olán

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Pulmonary histoplasmosis is caused by inhaling Histoplasma capsulatum. Less than 1% develops the disease. Risk factors in immunocompetent individuals are environmental exposures in endemic areas. The objective of this study is to determine the frequency, clinical, and microbiological characteristics in immunocompetent patients. A retrospective case series study of patients diagnosed with pulmonary histoplasmosis was performed in a respiratory care unit in Mexico City from 2000 to 2020. Each patient had bronchial lavage, and three patients underwent thoracoscopy for the lung tissue sample taken for the culture in Sabouraud Dextrose Agar. Twelve patients were identified, 8 males and 4 females; the predominant symptoms were fever (83%), dyspnea (75%), chest pain (66%), hemoptysis (41%), and weight loss (33%). The computed tomography of the chest showed the following findings: patchy consolidation 12 (100%), hilar adenopathy 6 (50%), pleural effusion 6 (50%), caverns 3 (25%), and solitary pulmonary nodule in one patient (8%). Histoplasma capsulatum was found in the culture of all twelve patients. The signs and symptoms of the disease are mediated by the immune status of the host. The clinical picture is often confused with systemic diseases. It is important to have a high degree of clinical suspicion to make a timely diagnosis.

show abstract

Section: Discussionmentioning

confidence: 44%

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Solís

Santibáñez

Olán

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

show abstract

“…Among the most widespread infectious diseases globally, the ones caused by fungi are worth mentioning. Almost one billion cases of either superficial or cutaneous mycoses are recorded around the world per year and they account for 1.6 million global deaths [ 93 ]. In this scenario, the search for agents able to prevent or subvert mycoses is a global priority.…”

Section: Antimicrobial Activitiesmentioning

confidence: 99%

Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation

2021

View full text Add to dashboard Cite

Ebselen is the leader of selenorganic compounds, and starting from its identification as mimetic of the key antioxidant enzyme glutathione peroxidase, several papers have appeared in literature claiming its biological activities. It was the subject of several clinical trials and it is currently in clinical evaluation for the treatment of COVID-19 patients. Given our interest in the synthesis and pharmacological evaluation of selenorganic derivatives with this review, we aimed to collect all the papers focused on the biological evaluation of ebselen and its close analogues, covering the timeline between 2016 and most of 2021. Our analysis evidences that, even if it lacks specificity when tested in vitro, being able to bind to every reactive cysteine, it proved to be always well tolerated in vivo, exerting no sign of toxicity whatever the administered doses. Besides, looking at the literature, we realized that no review article dealing with the synthetic approaches for the construction of the benzo[d][1,2]-selenazol-3(2H)-one scaffold is available; thus, a section of the present review article is completely devoted to this specific topic.

show abstract

“…Endemic fungal diseases such as histoplasmosis, coccidioidomycosis, and paracoccidioidomycosis are either increasing or are underreported [17,18]. They generally carry primary resistance to echinocandins, and fluconazole resistance is noted amongst histoplasmosis isolates.…”

Section: Thermally Dimorphic Fungimentioning

confidence: 99%

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Seiler

Ostrosky‐Zeichner

2021

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Purpose of Review This review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described. Recent Findings Agricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development. Summary Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes' indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed. Keywords Antifungal drugs . Antifungal resistance . Invasive fungal infections . Candida auris . Novel therapies . Review This article is part of the Topical Collection on Current Management of Fungal Infections

show abstract

Endemic mycoses: epidemiology and diagnostic strategies

Cited by 15 publications

References 101 publications

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Contact Info

Product

Resources

About